Method of treating androgen independent prostate cancer
US9040574B2 · kind B2 · utility
1,030Cited by
2References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 20, 2012 |
| Grant date | May 26, 2015 |
| Priority date | — |
| Expiry date | Sep 20, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/2004
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.